ArticleJournal of the American Academy of Dermatology2020
Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center.
Article in Journal of the American Academy of Dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Skin Cancer in People of Color: A Systematic Review.American journal of clinical dermatology · 2022Pooled it
- Persistent racial and socioeconomic inequities in mycosis fungoides survival: a population-based study.Frontiers in public health · 2026Article
- Beyond traditional staging system: Tumor-Node-Metastasis-Blood staging system improves treatment decisions and prognostic stratification in cancer patients.Frontiers in oncology · 2026Review
- Established and emerging prognostic factors in mycosis fungoides and Sézary syndrome.Frontiers in oncology · 2026Review
- Downregulation of miRNA-590 and miRNA-182 in Early-Stage Mycosis Fungoides in Skin of Color Patients.Cureus · 2025Article
- Concurrent papular and dyshidrotic mycosis fungoides: A case report in a patient with skin of color.JAAD case reports · 2024Article
- Racial Disparities in Mycosis Fungoides/Sézary Syndrome-A Single-Center Observational Study of 292 Patients.Clinical lymphoma, myeloma & leukemia · 2024Observational
- Reply to Wu et al's US SEER analysis of sepsis in Black patients with CTCL.Journal of the American Academy of Dermatology · 2024Article
- Mycosis fungoides and Sézary syndrome.Blood research · 2023Review
- Article
- Retrospective analysis of sepsis in cutaneous T-cell lymphoma reveals significantly greater risk in Black patients.Journal of the American Academy of Dermatology · 2023Article
- Article
- Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management.American journal of hematology · 2023Article
- African American and Caucasian patients with Sézary syndrome have no differences in outcomes at an ethnically diverse urban medical center.Leukemia & lymphoma · 2022Article
- The impact of gender, age, race/ethnicity, and stage on quality of life in a spectrum of cutaneous lymphomas.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.American journal of hematology · 2021Article
- Cutaneous T cell lymphoma.Nature reviews. Disease primers · 2021Review
- Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: a subgroup analysis of the phase III MAVORIC trial.Leukemia & lymphoma · 2021Article
- Acceleration of cutaneous T-cell lymphoma following dupilumab administration.JAAD case reports · 2021Article
- Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundThe prevalence of mycosis fungoides/Sézary syndrome (MF/SS) is higher in the black population than in the white population in the United States and worse outcomes have been observed in black patients.
objectiveTo describe the outcomes and to identify prognostic factors in African American and black patients with MF/SS.
methodsClinical features and follow-up data were analyzed in 157 self-identified African American or black patients seen during 1994-2018.
resultsWe included 122 patients with early stage MF and 35 patients with advanced-stage disease (median follow-up of 25 months). Overall, >80% of the patients who died from disease or progressed had erythema or hyperpigmentation without hypopigmentation. Patients with hypopigmentation, either as the sole manifestation or in combination with other lesions, had better overall survival (P = .002) and progression-free survival (P = .014). Clinical stage, TNMB classification, plaque disease, and elevated serum lactate dehydrogenase were also significantly associated with outcomes. Demographic and socioeconomic parameters were not associated with prognosis. LIMITATIONS: A retrospective study at a single cancer center.
conclusionMF/SS manifestations and outcomes in African American and black patients are heterogeneous. Demographic and socioeconomic factors do not seem to have a prognostic role, while clinical characteristics might help in the stratification of risk of progression and shorter survival, allowing for individually tailored therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.